Literature DB >> 21709231

Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs).

Hideyuki Yanai1, Shiho Chiba, Tatsuma Ban, Yukana Nakaima, Takashi Onoe, Kenya Honda, Hideki Ohdan, Tadatsugu Taniguchi.   

Abstract

The activation of innate immune responses by nucleic acids is central to the generation of host responses against pathogens; however, nucleic acids can also trigger the development and/or exacerbation of pathogenic responses such as autoimmunity. We previously demonstrated that the selective activation of nucleic acid-sensing cytosolic and Toll-like receptors is contingent on the promiscuous sensing of nucleic acids by high-mobility group box proteins (HMGBs). From this, we reasoned that nonimmunogenic nucleotides with high-affinity HMGB binding may function as suppressing agents for HMGB-mediated diseases, particularly those initiated and/or exacerbated by nucleic acids. Here we characterize an array of HMGB-binding, nonimmunogenic oligodeoxynucleotides (ni-ODNs). Interestingly, we find that binding affinity is rather independent of nucleotide sequence, but is instead dependent on length and structure of the deoxyribose backbone. We further show that these ni-ODNs can strongly suppress the activation of innate immune responses induced by both classes of nucleic acid-sensing receptors. We also provide evidence for the suppressive effect of an ni-ODN, termed ISM ODN, on the induction of adaptive immune responses and in mouse models of sepsis and autoimmunity. We discuss our findings in relation to the critical role of HMGBs in initiating immune responses and the possible use of these ni-ODNs in therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21709231      PMCID: PMC3136288          DOI: 10.1073/pnas.1108535108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Recognition of microorganisms and activation of the immune response.

Authors:  Ruslan Medzhitov
Journal:  Nature       Date:  2007-10-18       Impact factor: 49.962

Review 2.  HMGB1 loves company.

Authors:  Marco E Bianchi
Journal:  J Leukoc Biol       Date:  2009-05-04       Impact factor: 4.962

3.  Innate immunity: cytoplasmic DNA sensing by the AIM2 inflammasome.

Authors:  Kate Schroder; Daniel A Muruve; Jürg Tschopp
Journal:  Curr Biol       Date:  2009-03-24       Impact factor: 10.834

4.  A selective contribution of the RIG-I-like receptor pathway to type I interferon responses activated by cytosolic DNA.

Authors:  Myoung Kwon Choi; ZhiChao Wang; Tatsuma Ban; Hideyuki Yanai; Yan Lu; Ryuji Koshiba; Yukana Nakaima; Sho Hangai; David Savitsky; Makoto Nakasato; Hideo Negishi; Osamu Takeuchi; Kenya Honda; Shizuo Akira; Tomohiko Tamura; Tadatsugu Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-01       Impact factor: 11.205

5.  Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis.

Authors:  Monica Marta; Asa Andersson; Magnus Isaksson; Olle Kämpe; Anna Lobell
Journal:  Eur J Immunol       Date:  2008-02       Impact factor: 5.532

6.  The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation.

Authors:  Tobias Haas; Jochen Metzger; Frank Schmitz; Antje Heit; Thomas Müller; Eicke Latz; Hermann Wagner
Journal:  Immunity       Date:  2008-03       Impact factor: 31.745

Review 7.  The role of innate immunity in the induction of autoimmunity.

Authors:  David S Pisetsky
Journal:  Autoimmun Rev       Date:  2008-08-15       Impact factor: 9.754

8.  TLR9 signals after translocating from the ER to CpG DNA in the lysosome.

Authors:  Eicke Latz; Annett Schoenemeyer; Alberto Visintin; Katherine A Fitzgerald; Brian G Monks; Cathrine F Knetter; Egil Lien; Nadra J Nilsen; Terje Espevik; Douglas T Golenbock
Journal:  Nat Immunol       Date:  2004-01-11       Impact factor: 25.606

9.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.

Authors:  Paola Scaffidi; Tom Misteli; Marco E Bianchi
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

Review 10.  The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Alfredo Criollo; Carla Ortiz; Rosette Lidereau; Christophe Mariette; Nathalie Chaput; Jean-Paul Mira; Suzette Delaloge; Fabrice André; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Immunol Rev       Date:  2007-12       Impact factor: 12.988

View more
  22 in total

1.  High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor.

Authors:  Hulda Sigridur Hreggvidsdóttir; Anna M Lundberg; Ann-Charlotte Aveberger; Lena Klevenvall; Ulf Andersson; Helena Erlandsson Harris
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

Review 2.  HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.

Authors:  Helena Erlandsson Harris; Ulf Andersson; David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

3.  Deficiency of the novel high mobility group protein HMGXB4 protects against systemic inflammation-induced endotoxemia in mice.

Authors:  Xiangqin He; Kunzhe Dong; Jian Shen; Guoqing Hu; Jinhua Liu; Xiuhua Kang; Liang Wang; Reem T Atawia; Islam Osman; Robert W Caldwell; Meixiang Xiang; Wei Zhang; Zeqi Zheng; Liwu Li; David J R Fulton; Keyu Deng; Hongbo Xin; Jiliang Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-16       Impact factor: 11.205

Review 4.  The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis.

Authors:  Huan Yang; Daniel J Antoine; Ulf Andersson; Kevin J Tracey
Journal:  J Leukoc Biol       Date:  2013-02-27       Impact factor: 4.962

5.  Effects of cartilage impact with and without fracture on chondrocyte viability and the release of inflammatory markers.

Authors:  Josef A Stolberg-Stolberg; Bridgette D Furman; N William Garrigues; Jaewoo Lee; David S Pisetsky; Nancy A Stearns; Louis E DeFrate; Farshid Guilak; Steven A Olson
Journal:  J Orthop Res       Date:  2013-04-25       Impact factor: 3.494

Review 6.  The role of high mobility group protein B3 (HMGB3) in tumor proliferation and drug resistance.

Authors:  Bin Wen; Ying-Ting Wei; Kui Zhao
Journal:  Mol Cell Biochem       Date:  2021-01-11       Impact factor: 3.396

7.  Dynamic localization and the associated translocation mechanism of HMGBs in response to GCRV challenge in CIK cells.

Authors:  Youliang Rao; Jianguo Su; Chunrong Yang; Nana Yan; Xiaohui Chen; Xiaoli Feng
Journal:  Cell Mol Immunol       Date:  2014-07-21       Impact factor: 11.530

Review 8.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

9.  Conformation and protein interactions of intramolecular DNA and phosphorothioate four-way junctions.

Authors:  Maria Troisi; Mitchell Klein; Andrew C Smith; Gaston Moorhead; Yonatan Kebede; Raymond Huang; Elliott Parker; Hector Herrada; Elizabeth Wade; Samara Smith; Payson Broome; Jonah Halsell; Louis Estevez; Anthony J Bell
Journal:  Exp Biol Med (Maywood)       Date:  2020-12-20

10.  Regulatory role of suppressive motifs from commensal DNA.

Authors:  N Bouladoux; J A Hall; J R Grainger; L M dos Santos; M G Kann; V Nagarajan; D Verthelyi; Y Belkaid
Journal:  Mucosal Immunol       Date:  2012-05-23       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.